3.1 Descriptive analysis
After data cleaning, 17,710,899 reports in the FAERS database were of use. Overall, from January 2004 to March 2022, there were 3694 reports listing voriconazole were identified as PS, the number of hepatic dysfunction events was 646 (17.48%). The clinical characteristics of patients with voriconazole induced hepatic dysfunction were described inTable 1 . The hepatic disorders associated with voriconazole were slightly higher in male than in female (56.50% vs. 33.90%, P<0.05), and 27.40% of them are elderly patients (≥65 years old). The fatality rate of the reported hepatic disorders was 9.75%, which is lower than non-hepatic disorders.
The median time to event of the hepatic dysfunction events was 8 (IQR 2-28) days, and 62.20% of patients developed hepatic dysfunction in 15 days of voriconazole use (Fig. 1 ).